Overview
Updated 14 Jul 2026
Kieren Mather, MD, is Vice President, Medical – Incretin and Diabetes Breakthroughs, Early Clinical Research, Eli Lilly and Company. The public record shows 423 publications with 16,851 citations (h-index 58), centered on Type 2 Diabetes, Obesity. It also documents an investigator role on 7 registered clinical trials, 8 NIH-funded awards (2003–2018).
- Most recent indexed publication: 2026 · Diabetes, obesity & metabolism
- Top research focus: Type 2 Diabetes
- 7 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 25 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism
Sponsor: Indiana University
InvestigatorCompletedNCT02563834 - Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Sponsor: Indiana University
InvestigatorPhase 2/PHASE3CompletedNCT01607450 - Early Diabetes Intervention Program
Sponsor: Indiana University
InvestigatorPhase 4CompletedNCT01470937
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
Updated 14 Jul 2026
8 NIH research awards on record, funded 2003–2018 per NIH RePORTER. The latest:
- 14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 – Research Project
Indiana University Indianapolis
FY2018$348,830U01DK048406 - Cardiovascular effects of GLP-1 in obesity/metabolic syndrome
Indiana University Indianapolis
FY2017$660,047R01HL117620
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
Diabetes, obesity & metabolism
2026 - Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.
Diabetes, obesity & metabolism
2025 - A Post-Hoc Analysis of Depressive Disorders in Patients with Type 2 Diabetes.
Healthcare (Basel, Switzerland)
2025
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
975 W Walnut St, IB 424, Indianapolis, IN 46202
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Board Certified
Endocrinology, Diabetes & Metabolism (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Secondary affiliationsappointments beyond the home institution
- Professor of Medicine
Division of Endocrinology & Metabolism, Indiana University School of Medicine (Indianapolis, IN), retained academic appointment from prior 20-year IU faculty career
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Media & interviewspress, podcasts and appearances
- Confirmed speaker
TIDES Europe 2026 (Oligonucleotide and Peptide Therapeutics conference), presenting on Oral GLP-1 Clinical Program / Amylin Phase 2 Program Update, Nov 5
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →informaconnect.com ↗ - Featured interview
"What's Coming Next for GLP-1 and Metabolic Disease Treatment," The Physiologist Magazine (American Physiological Society), May 2025, discusses Lilly's diabetes/obesity pipeline (tirzepatide …
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiology.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by otherswhere others cite or feature them
- Other
informaconnect.com/tides-europe/speakers/kieren-mather-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →informaconnect.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.